Hologic wraps up Biotheranostics acquisition

2020 01 02 21 24 9838 Hologic Rsna 2019 400

Hologic has completed the acquisition of cancer test developer Biotheranostics. Hologic is gaining access to two laboratory-developed tests as part of the deal.

Hologic had unveiled plans to acquire Biotheranostics for $230 million in January. Through the deal, Hologic gains two laboratory-developed tests -- the Breast Cancer Index, which predicts effects of endocrine therapy in breast cancer patients and CancerType ID, which aids in the molecular characterization of uncertain and unknown cancers.

Page 1 of 1